Core Insights - The company reported better-than-expected performance for 1H25, with revenue of 312 million yuan (+28.2% YoY) and net profit attributable to shareholders of 166 million yuan (+4.3% YoY) [1][2] - The growth in revenue is attributed to a rapid increase in the number of collaborative projects [1] Financial Performance - Non-IFRS EBIT for 1H25 reached 72.69 million yuan (+36.4% YoY), with a corresponding profit margin of 23.3% (+1.4 percentage points YoY) [1][2] - The gross margin for 1H25 was reported at 59.0% (-1.6 percentage points YoY), influenced by increased costs associated with digital marketing projects for pharmaceutical clients [2] Revenue Breakdown - Revenue by business segment for 1H25: Precision Marketing and Enterprise Solutions at 292 million yuan (+29.6% YoY), Medical Knowledge Solutions at 9.195 million yuan (+9.2% YoY), and Intelligent Patient Management Solutions at 10.46 million yuan (+11.5% YoY) [1] - Revenue by region for 1H25: Domestic revenue at 304 million yuan (+28.0% YoY) and overseas revenue at 77.55 million yuan (+37.5% YoY) [1] Client Engagement - The number of clients covered by Precision Education and Enterprise Solutions increased to 191 (+20.9% YoY), with a total of 445 projects (+32.4% YoY) [1] - The average number of collaborative projects per enterprise increased to approximately 2.3 in 1H25, compared to 2.1 in 1H24 [1] Dividend Policy - The company plans to distribute a dividend of 0.1166 yuan per share, with a total dividend payout of 85.615 million yuan, representing a payout ratio of approximately 55% [2] Product Development - The company launched AI products such as MedSeeker, MedPaper, and MedAssister, aimed at assisting physicians in clinical decision-making and improving research efficiency [3] - A new content generation module for pharmaceutical clients was introduced, which can reduce labor costs by 50% while ensuring content professionalism and compliance [3] Valuation and Forecast - The company maintains its target price at 17.5 HKD, based on a 39x EV/EBIT valuation for 2025, with a current trading multiple of approximately 28x [3]

Investment Rating - The report maintains an "Outperform" rating for Medlive Technology with a target price of HKD 15.00, reflecting a potential upside from the current price of HKD 14.07 [2][15]. Core Insights - Medlive Technology reported a revenue of RMB 310 million in H1 2025, representing a growth of 28.2%. The revenue from precision marketing and enterprise solutions was RMB 290 million, up 29.6%, driven by an increase in marketing products to 445 [3][11]. - The company launched several AI products, enhancing user engagement and increasing monthly active users to 2.78 million, a rise of 11.2% [13]. - The operational net profit margin improved to 23.3%, with an adjusted net profit of RMB 72.62 million, reflecting a growth of 36.2% [12]. Financial Performance Summary - Revenue projections for 2025 to 2027 are RMB 730 million, RMB 940 million, and RMB 1.23 billion, with consistent growth rates of 30% [5][14]. - The adjusted net profit forecast for the same period is RMB 320 million, RMB 350 million, and RMB 390 million, with growth rates of -1%, 7%, and 13% respectively [5][14]. - The gross profit margin is expected to remain stable at 58.6% across the forecast period [4][14]. Operational Efficiency - The company achieved a gross profit margin of 59.0% in H1 2025, with a combined improvement in sales, administrative, and R&D expense ratios by 2.3 percentage points [4][12]. - The net profit for H1 2025 was RMB 160 million, reflecting a 5.0% increase [4][12]. Market Position and Strategy - Medlive Technology is deepening collaborations with domestic pharmaceutical companies and enhancing its AI capabilities to strengthen its competitive position in the innovative pharmaceutical industry [5][15]. - The report highlights the importance of AI in driving user engagement and improving the efficiency of medical professionals [13][15].